Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression

被引：49

作者：

Oki, Y. ^{[1
]}

Buglio, D. ^{[1
]}

Zhang, J. ^{[2
]}

Ying, Y. ^{[2
]}

Zhou, S. ^{[2
]}

Sureda, A. ^{[3
]}

Ben-Yehuda, D. ^{[4
]}

Zinzani, P. L. ^{[5
]}

Prince, H. M. ^{[6
,7
]}

Harrison, S. J. ^{[6
,7
]}

Kirschbaum, M. ^{[8
]}

Johnston, P. B. ^{[9
]}

Shen, A. ^{[10
]}

von Tresckow, B. ^{[11
]}

Younes, A. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA

[3] Hosp Santa Creu & Sant Pau, Dept Hematol, Barcelona, Spain

[4] Hadassah Med Org, Div Hematol, Jerusalem, Israel

[5] Univ Bologna, Inst Hematol & Med Oncol, Bologna, Italy

[6] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[7] Univ Melbourne, Melbourne, Vic, Australia

[8] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplant, Duarte, CA USA

[9] Mayo Clin, Dept Hematol, Rochester, MN USA

[10] Novartis Pharmaceut, Florham Pk, NJ USA

[11] Univ Hosp Cologne, Cologne, Germany

来源：

BLOOD CANCER JOURNAL | 2014年 / 4卷

关键词：

PHASE-II; SAFETY; MICROENVIRONMENT; TRANSPLANTATION; PIDILIZUMAB; BLOCKADE; TRIAL;

D O I：

10.1038/bcj.2014.58

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：e236 / e236

页数：4

共 14 条

[1] The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape [J].

Aldinucci, Donatella ;

Gloghini, Annunziata ;

Pinto, Antonio ;

De Filippi, Rosaria ;

Carbone, Antonino .

JOURNAL OF PATHOLOGY, 2010, 221 (03) :248-263

[2] Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial [J].

Armand, Philippe ;

Nagler, Arnon ;

Weller, Edie A. ;

Devine, Steven M. ;

Avigan, David E. ;

Chen, Yi-Bin ;

Kaminski, Mark S. ;

Holland, H. Kent ;

Winter, Jane N. ;

Mason, James R. ;

Fay, Joseph W. ;

Rizzieri, David A. ;

Hosing, Chitra M. ;

Ball, Edward D. ;

Uberti, Joseph P. ;

Lazarus, Hillard M. ;

Mapara, Markus Y. ;

Gregory, Stephanie A. ;

Timmerman, John M. ;

Andorsky, David ;

Or, Reuven ;

Waller, Edmund K. ;

Rotem-Yehudar, Rinat ;

Gordon, Leo I. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (33) :4199-4206

[3] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

[4] HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma [J].

Buglio, Daniela ;

Khaskhely, Noor M. ;

Voo, Kui Shin ;

Martinez-Valdez, Hector ;

Liu, Yong-Jun ;

Younes, Anas .

BLOOD, 2011, 117 (10) :2910-2917

[5] Revised response criteria for malignant lymphoma [J].

Cheson, Bruce D. ;

Pfistner, Beate ;

Juweid, Malik E. ;

Gascoyne, Randy D. ;

Specht, Lena ;

Horning, Sandra J. ;

Coiffier, Bertrand ;

Fisher, Richard I. ;

Hagenbeek, Anton ;

Zucca, Emanuele ;

Rosen, Steven T. ;

Stroobants, Sigrid ;

Lister, T. Andrew ;

Hoppe, Richard T. ;

Dreyling, Martin ;

Tobinai, Kensei ;

Vose, Julie M. ;

Connors, Joseph M. ;

Federico, Massimo ;

Diehl, Volker .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586

[6] Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma [J].

Hamid, Omid ;

Robert, Caroline ;

Daud, Adil ;

Hodi, F. Stephen ;

Hwu, Wen-Jen ;

Kefford, Richard ;

Wolchok, Jedd D. ;

Hersey, Peter ;

Joseph, Richard W. ;

Weber, Jeffrey S. ;

Dronca, Roxana ;

Gangadhar, Tara C. ;

Patnaik, Amita ;

Zarour, Hassane ;

Joshua, Anthony M. ;

Gergich, Kevin ;

Elassaiss-Schaap, Jeroen ;

Algazi, Alain ;

Mateus, Christine ;

Boasberg, Peter ;

Tumeh, Paul C. ;

Chmielowski, Bartosz ;

Ebbinghaus, Scot W. ;

Li, Xiaoyun Nicole ;

Kang, S. Peter ;

Ribas, Antoni .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (02) :134-144

[7] Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant [J].

Harrison, Simon J. ;

Hsu, Andy K. ;

Neeson, Paul ;

Younes, Anas ;

Sureda, Anna ;

Engert, Andreas ;

Prince, H. Miles ;

Li, Martha ;

Savage, Paula ;

Bugarini, Roberto ;

Williams, Denise ;

Squier, Margaret ;

Ritchie, David S. .

LEUKEMIA & LYMPHOMA, 2014, 55 (05) :1053-1060

[8] The Histone Deacetylase Inhibitor LBH589 (Panobinostat) Modulates the Crosstalk of Lymphocytes with Hodgkin Lymphoma Cell Lines [J].

Klein, Jan M. ;

Henke, Alexander ;

Sauer, Maike ;

Bessler, Martina ;

Reiners, Katrin S. ;

Engert, Andreas ;

Hansen, Hinrich P. ;

von Strandmann, Elke Pogge .

PLOS ONE, 2013, 8 (11)

[9] The microenvironment in classical Hodgkin lymphoma: An actively shaped and essential tumor component [J].

Liu, Yuxuan ;

Sattarzadeh, Ahmad ;

Diepstra, Arjan ;

Visser, Lydia ;

van den Berg, Anke .

SEMINARS IN CANCER BIOLOGY, 2014, 24 :15-22

[10] Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma [J].

Marri, Preethi Reddy ;

Hodge, Lucy S. ;

Maurer, Matthew J. ;

Ziesmer, Steven C. ;

Slager, Susan L. ;

Habermann, Thomas M. ;

Link, Brian K. ;

Cerhan, James R. ;

Novak, Anne J. ;

Ansell, Stephen M. .

CLINICAL CANCER RESEARCH, 2013, 19 (24) :6812-6819

← 1 2 →